Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Disease symbols : SNY save search
FDA Approves First Gene Therapy for Rare Pediatric Disease
Published: 2024-03-18 (Crawled : 23:00) - biospace.com/
PRGO | $29.94 -0.33% -0.6% 970K
|
Health Technology
|
| O: 0.33%
H: 0.13%
C: -1.51%
JNJ | News | $145.74 0.67% -0.18% 7M
|
Health Technology
|
| O: 0.2%
H: 0.08%
C: -1.14%
ABT | News | $105.27 -0.6% -0.38% 5.9M
|
Health Technology
|
| O: 1.71%
H: 0.36%
C: -2.52%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: -0.81%
H: 0.0%
C: 0.0%
fda rare first disease therapy
Incyte Gets Phase II Win, Targets Blockbuster Dupixent in Skin Disease
Published: 2024-03-11 (Crawled : 16:00) - biospace.com/
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: 0.57%
H: 0.0%
C: 0.0%
disease dupixent skin
Rare Disease Drug Development Urgently Needs More Funding, Experts Say
Published: 2024-02-29 (Crawled : 06:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -1.6%
H: 0.0%
C: 0.0%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: -0.11%
H: 0.0%
C: 0.0%
rare drug disease
Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria
Published: 2024-02-24 (Crawled : 16:20) - globenewswire.com
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
disease urticaria results
Innovent Announces Primary Endpoint Met in the Phase 3 Clinical Trial (RESTORE-1) of IBI311 (Anti-IGF-1R Antibody) in Treating Thyroid Eye Disease and Plans to Submit NDA to the NMPA
Published: 2024-02-20 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 2.72%
H: 0.0%
C: -0.8%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: 2.53%
H: 0.0%
C: 0.0%
ibi311 disease thyroid eye trial
Hydroxychloroquine Market to Reach $2.86 Billion by 2028 Amidst Rising Demand for Autoimmune Disease Treatments
Published: 2024-02-13 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -2.71%
H: 0.0%
C: 0.0%
NVS | $92.57 -0.55% 0.27% 840K
|
Health Technology
|
| O: -0.02%
H: 0.24%
C: 0.01%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: 0.0%
disease reach market
Listeria Monocytogenes Infections Treatment Global Market Report 2024: Global Expansion in Listeria Monocytogenes Treatment Sector Predicted Amid Rising Foodborne Disease Incidence
Published: 2024-02-14 (Crawled : 00:00) - prnewswire.com
GLAXF | $20.2 0.65% -14.18% 40
|
Health Technology
|
| O: -2.14%
H: 0.0%
C: -0.63%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -2.71%
H: 0.0%
C: 0.0%
AZNCF | $138.24 -1.36% -4.19% 800
|
Health Technology
|
| O: 0.87%
H: 0.21%
C: -2.23%
GSK | $39.27 -0.83% 0.26% 1.9M
|
Health Technology
|
| O: 0.89%
H: 0.41%
C: 0.1%
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: 0.38%
H: 2.44%
C: 1.54%
VRTX | News | $393.48 0.1% 0.1% 780K
|
Health Technology
|
| O: 0.56%
H: 0.49%
C: -0.12%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: 0.0%
BIIB | $190.52 -0.85% -0.84% 1.3M
|
Health Technology
|
| O: 0.16%
H: 0.43%
C: -2.76%
AZN | $68.36 -0.25% -0.25% 3.6M
|
Health Technology
|
| O: 0.28%
H: 0.93%
C: 0.75%
AMGN | $262.75 -0.5% -0.49% 1.4M
|
Health Technology
|
| O: -0.21%
H: 0.34%
C: 0.07%
disease report treatment expansion global infections market
Animal Therapeutics and Diagnostics Global Market Report 2024 - Dermatological Disease Management in Animals to Propel Market Growth
Published: 2024-02-13 (Crawled : 23:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -2.71%
H: 0.0%
C: 0.0%
ZTS | News | $153.11 1.05% 0.0% 4.4M
|
Health Technology
|
| O: 0.93%
H: 0.7%
C: -0.6%
TMO | News | $541.52 -1.05% -0.1% 1.8M
|
Health Technology
|
| O: 0.56%
H: 1.3%
C: 1.22%
QGEN | $39.47 0.61% 0.0% 950K
|
Health Technology
|
| O: -1.14%
H: 1.3%
C: 1.2%
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: 0.38%
H: 2.44%
C: 1.54%
ELAN | $13.57 1.19% 0.0% 3.8M
|
Process Industries
|
| O: 1.53%
H: 1.16%
C: 0.82%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: 0.0%
QGEN | $39.47 0.61% 0.0% 950K
|
Health Technology
|
| O: -1.14%
H: 1.3%
C: 1.2%
PAHC | $13.04 1.32% 1.45% 79K
|
Health Technology
|
| O: 1.32%
H: 4.7%
C: 4.09%
NEOG P | $11.93 -1.73% -1.68% 2.9M
|
Health Technology
|
| O: -0.24%
H: 4.39%
C: 3.29%
management propel disease report animal global animals dermatological diagnostics therapeutics growth market
Liver Disease Therapeutics Competitive Landscape and Market Forecasts to 2028
Published: 2024-02-12 (Crawled : 20:00) - prnewswire.com
ALPMY | $9.47 0.11% -1.11% 520K
|
Manufacturing
|
| O: 0.37%
H: 0.74%
C: 0.28%
BMY | $48.3 0.96% 0.33% 8.9M
|
Health Technology
|
| O: -0.18%
H: 0.48%
C: -1.91%
ABBV | News | $164.66 0.25% -0.14% 3.6M
|
Health Technology
|
| O: 0.8%
H: 0.0%
C: 0.0%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
GILD | News | $66.16 -1.15% -1.16% 4.9M
|
Health Technology
|
| O: 0.32%
H: 0.11%
C: -1.55%
ALNY | News | $145.16 -0.11% -0.19% 400K
|
Health Technology
|
| O: -2.63%
H: 0.98%
C: -1.75%
liver disease therapeutics market
Global Pompe Disease Drugs Market: USD 294.7 Million Growth Forecasted at a CAGR of 4.16% between 2024 to 2028 - Technavio
Published: 2024-01-26 (Crawled : 00:20) - prnewswire.com
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
ALPMF | $9.17 -4.42% 43.47% 16K
|
Health Technology
| Email alert
Add to watchlist
ALPMY | $9.47 0.11% -1.11% 520K
|
Manufacturing
| Email alert
Add to watchlist
disease million global growth
Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline
Published: 2024-01-23 (Crawled : 07:00) - globenewswire.com
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: -2.05%
H: 0.0%
C: 0.0%
INBX | $34.45 -0.46% -0.41% 420K
|
Health Technology
|
| O: 6.51%
H: 4.73%
C: 2.25%
rare disease pipeline acquire potential sanofi
Global Respiratory Disease Vaccine Market Set for Growth, Fueled by Aging Populations and Vaccine Mandates - Trends, Opportunities, and Forecasts, 2018-2028F
Published: 2024-01-22 (Crawled : 17:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.71%
H: 0.0%
C: -0.15%
AZNCF | $138.24 -1.36% -4.19% 800
|
Health Technology
|
| O: 2.63%
H: 0.8%
C: 0.75%
JNJ | News | $145.74 0.67% -0.18% 7M
|
Health Technology
|
| O: 0.6%
H: 0.0%
C: 0.0%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: -0.21%
H: 0.0%
C: 0.0%
AZN | $68.36 -0.25% -0.25% 3.6M
|
Health Technology
|
| O: 1.8%
H: 0.14%
C: -0.89%
disease vaccine respiratory global set market
Chronic Disease Markets for Sustained Released Injectables: The Trend toward Self-Administration
Published: 2024-01-15 (Crawled : 12:00) - prnewswire.com
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
disease
Skye Bioscience Receives IND Clearance for Phase 2 Clinical Trial of Nimacimab in Obesity and Chronic Kidney Disease
Published: 2024-01-09 (Crawled : 16:00) - biospace.com/
SKYE | $16.97 -2.25% -2.94% 70K
|
Transportation and Warehousing
|
| O: -7.02%
H: 29.11%
C: 15.56%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: 0.0%
obesity disease kidney bioscience clearance trial
Sanofi Drops Acquisition of Maze’s Pompe Disease Drug After FTC Challenge
Published: 2023-12-12 (Crawled : 14:00) - biospace.com/
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: 0.43%
H: 0.0%
C: 0.0%
drug disease acquisition sanofi
Maze Therapeutics Announces FTC Action Seeking to Block Collaboration and License Agreement with Sanofi Regarding MZE001, a Potential Oral Substrate Reduction Therapy for Pompe Disease
Published: 2023-12-11 (Crawled : 00:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.5%
H: 1.67%
C: 0.1%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: 2.15%
H: 0.0%
C: 0.0%
mze001 disease license collaboration therapeutics potential agreement therapy sanofi
Press Release: Sarclisa® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone
Published: 2023-12-11 (Crawled : 01:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.5%
H: 1.67%
C: 0.1%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: 2.15%
H: 0.0%
C: 0.0%
sarclisa disease plus
Neuromuscular Disease Therapeutics Market size to grow by USD 65.13 billion from 2022-2027| Aquestive Therapeutics Inc., Bausch Health Companies Inc., Biogen Inc. and more among the major companies in the market- Technavio
Published: 2023-12-01 (Crawled : 19:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
NVSEF | $93.6375 6.88% 82K
|
Health Technology
| Email alert
Add to watchlist
BHC | $8.6 -0.69% 0.0% 2.2M
|
Health Technology
| Email alert
Add to watchlist
BIIB | $190.52 -0.85% -0.84% 1.3M
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
| Email alert
Add to watchlist
BCLI | $0.5143 -4.9% -7.51% 1.1M
|
Health Technology
| Email alert
Add to watchlist
VTRS | $11.12 0.18% 0.09% 2.3M
|
Health Technology
| Email alert
Add to watchlist
NVS | $92.57 -0.55% 0.27% 840K
|
Health Technology
| Email alert
Add to watchlist
disease companies health therapeutics market
Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment
Published: 2023-11-30 (Crawled : 15:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.35%
H: 0.0%
C: 0.0%
TEVA | $12.78 -3.03% -1.8% 8.4M
|
Health Technology
|
| O: -0.52%
H: 3.73%
C: 1.87%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: -1.09%
H: 0.0%
C: 0.0%
disease treatment collaboration teva deal
Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease
Published: 2023-11-27 (Crawled : 07:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.36%
H: 0.0%
C: 0.0%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: 1.04%
H: 0.17%
C: 0.11%
REGN | $893.99 -0.8% -0.84% 450K
|
Health Technology
|
| O: 0.46%
H: 0.37%
C: -0.49%
dupixent fda disease approved positive copd potential submission
Gainers vs Losers
| 60% | 40% |
Top 10 Gainers
AGBA | News | $1.03 157.5% 57.94% 120M
|
Finance
ZCMD | $1.45 5.84% 52.1% 2.3M
|
Commercial Services
INVO | $1.52 100.0% 51.13% 5M
|
Health Technology
ISPC | $0.421 97.65% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.5 45.65% 470K
|
OST | $0.509 23.81% 45.26% 90K
|
GDHG | $0.263 21.76% 40.66% 3.1M
|
XPON | News | $3.15 63.21% 37.74% 16M
|
TIRX | $0.8 65.02% 30.74% 58M
|
BNTC | News | $6.82 42.08% 30.64% 3.5M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.